The Teleflex Freesolve RMS uses magnesium alloy and bioabsorbable coating technology to provide vessel support during and ...

Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an ...

The Freesolve Resorbable Magnesium Scaffold previously received the same designation for below-the-knee interventions. This update covers minimally invasive coronary procedures.

Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) ...

Teleflex (TFX) said Thursday that the FDA granted Breakthrough Device Designation to its Freesolve Resorbable Magnesium Scaffold for percutaneous coronary intervention. The device ...

Medical technology company Teleflex (NYSE:TFX) reported Q1 CY2026 results beating Wall Street’s revenue expectations, with ...

Teleflex Incorporated (TFX) announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) to its Freesolve Resorbable Magnesium Scaffold (RMS) for ...

Teleflex reported Q1 2026 continuing operations revenue of $548.3 million, up 32.3% year over year on a GAAP basis, reflecting the impact of acquisitions. On a pro forma adjusted constant currency ...

Shares of Teleflex Inc. TFX rallied 1.13% to $131.15 Tuesday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.28% to 7,712.57 and ...

Former Medtronic VP and Renal Denervation GM Jason Fontana is now president and general manager of interventional cardiology ...

Teleflex Incorporated announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation (BDD) for its Freesolve? Resorbable Magnesium Scaffold (RMS) for ...